A5050136275- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Surgical Treatments
- Cancer Immunotherapy and Biomarkers
- Esophageal and GI Pathology
- Cancer survivorship and care
- Helicobacter pylori-related gastroenterology studies
- Genetic factors in colorectal cancer
- Intraperitoneal and Appendiceal Malignancies
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Palliative Care and End-of-Life Issues
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
Leipzig University
2016-2025
University Hospital Leipzig
2016-2025
Klinik und Poliklinik für Neurologie
2021-2025
University Hospital Carl Gustav Carus
2007-2025
Technical University of Munich
2004-2025
Klinikum rechts der Isar
2004-2025
München Klinik
2004-2025
University Medical Center Freiburg
2025
Medical University of Graz
2025
University Hospital Magdeburg
2025
Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, irinotecan (FOLFIRI) compared with FOLFIRI alone after failure initial treatment for mCRC by tumor KRAS status. Patients Methods mCRC, one prior chemotherapy regimen Eastern Cooperative...
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients advanced/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, that progressed one prior therapy, to pembrolizumab 200 mg every 3 weeks for up 2 years chemotherapy (investigator’s choice paclitaxel, docetaxel, irinotecan). Primary end points were...
Purpose The efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. In this trial, we compared the survival and safety NCRT with alone in patients ESCC. Patients Methods From June 2007 to December 2014, 451 potentially resectable thoracic ESCC, clinically staged as T1-4N1M0/T4N0M0, were randomly allocated (group CRT; n = 224) S; 227). group CRT, received vinorelbine 25 mg/m2 intravenously (IV) on days...
Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive chemotherapy. We examined the value of purely preoperative chemotherapy in a phase III trial strict staging surgical resection guidelines.
A previous study suggested that measurement of therapy-induced changes in tumor glucose metabolism by positron emission tomography (PET) with the analog [18F]fluorodeoxyglucose (FDG) allows to select patients most likely benefit from preoperative chemotherapy adenocarcinomas esophagogastric junction (AEG). The aim this was prospectively validate these findings using an a priori definition metabolic response.Sixty-five locally advanced AEGs were included. Tumor utilization quantitatively...
To evaluate the time course of therapy-induced changes in tumor glucose use during chemoradiotherapy esophageal squamous cell carcinoma (ESCC) and to correlate reduction metabolic activity with histopathologic response patient survival.Thirty-eight patients histologically proven intrathoracic ESCC (cT3, cN0/+, cM0) scheduled undergo a 4-week preoperative simultaneous followed by esophagectomy were included. Patients underwent positron emission tomography analog fluorodeoxyglucose (FDG-PET)...
<h3>Importance</h3> Effective treatment options are limited for patients with advanced, metastatic esophageal cancer progressing after 2 or more lines of systemic therapy. <h3>Objective</h3> To evaluate the efficacy and safety pembrolizumab squamous cell carcinoma (ESCC) adenocarcinoma esophagus gastroesophageal junction that progressed <h3>Design, Setting, Participants</h3> This phase 2, open-label, interventional, single-arm study, KEYNOTE-180, enrolled 121 from January 12, 2016, to March...
Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy with alone showed significant survival benefits for combined modality treatment of patients localized esophageal adenocarcinoma. However, head-to-head comparisons and applying contemporary protocols are lacking. The present trial was initiated to obtain valid information whether yields better in the adenocarcinoma.The ESOPEC is an investigator-initiated multicenter prospective...
Inhalt 1. Informationen zu dieser Leitlinie 462 1.1. Herausgeber 1.1.1. Federführende Fachgesellschaft 1.1.2. Kontakt 1.1.3. Verfügbare Dokumente zur 1.2. Besonderer Hinweis 1.3. Autoren 1.4. Ziele des Leitlinienprogramms Onkologie 2. Einführung 463 2.1. Geltungsbereich und Zweck 2.1.1. Zielsetzung Fragestellung 2.1.2. Adressaten 464 2.1.3. Verbreitung u. Implementierung d. Leitlinien 2.1.4. Finanzierung der Darlegung möglicher Interessenskonflikte 2.1.5. Gültigkeitsdauer...
Dysregulation of the mesenchymal-epithelial transition (MET) signaling pathway is associated with poor prognosis in gastroesophageal adenocarcinoma (GEC). We report results METGastric, a phase 3 trial MET inhibitor onartuzumab plus standard first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative, MET-positive, advanced GEC.
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines diagnosis, treatment and follow-up oesophageal cancer was published in 2016, covered management local/locoregional disease, limited locally advanced disease advanced/metastatic disease. At ESMO Asia Meeting November 2017 it decided by both Japanese (JSMO) to convene a special guidelines meeting immediately after JSMO Annual 2018. aim adapt 2016 take into account ethnic differences...